Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AL-794 in Healthy Volunteers
NCT03411421Phase 1Terminated
- Sponsor
- Alios BioPharma
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AL-794 in influenza (2 arms), sponsored by Alios BioPharma. Primary endpoints: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability up to 40 days, ALS-033719 Plasma Concentrations and 1 more. Started Mar 2018; status: terminated.
02
Drugs
AL-794
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03411421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411421.